Search
JAKAVI 20 MG, Comprimé pelliculé
Details
| --- | Description |
|---|---|
| Pack | Boite de 56 |
| Strength (Dosage) | 20 MG |
| Laboratory | NOVARTIS PHARMA MAROC |
| Ingredients | Ruxolitinib |
| Therapeutic class | Immunosuppresseur sélectif, inhibiteur des Janus kinases |
| ATC code | L01XE18 |
| PPH | $2,970.50 |
| PPV | $3,029.10 |
| Refundable | Yes |
| Refund base | $3,029.10 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Not specified |
| Uses | Myélofibrose (MF) Jakavi est indiqué dans le traitement de la splénomégalie ou des symptômes liés à la maladie chez l’adulte atteint de myélofibrose primitive (appelée également myélofibrose chronique idiopathique), de myélofibrose secondaire à la maladie de Vaquez (polycythémie vraie) ou de myélofibrose secondaire à la thrombocytémie essentielle. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications with one or more of the ingredients above
Medications under one or more of the therapeutic classes above
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem